Perjeta pertuzumab is employed to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy to enhance treatment outcomes.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label ...

The pathologic complete response rate was 66.3% in the nab-paclitaxel arm and 57.6% in the docetaxel-carboplatin arm. The combination of nab-paclitaxel, trastuzumab, and pertuzumab may provide ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

In the article that accompanies this editorial, 16 the authors report clinical outcomes from the Japanese phase III JBCRG-M06/EMERALD trial, which compared first-line eribulin plus dual human ...

Treatment for HER2-positive breast cancer depends on tumor size and spread but may involve a combination of chemotherapy, targeted therapy, monoclonal antibody therapy, and kinase inhibitors.

after a first course of chemotherapy and dual blockade and HER2 blockade with pertuzumab [Perjeta]/trastuzumab [Herceptin], usually treat with the maintenance treatment with pertuzumab/trastuzumab ...